Business
Voyageur Pharmaceuticals Ltd Submits Fourth Radiographic Contrast Product to Health Canada for Registration
(via TheNewswire) CALGARY, Alberta - TheNewswire - January 10 th ,...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Pharmaceuticals Ltd Submits Fourth Radiographic Contrast Product to Health Canada for Registration(via TheNewswire)\n \n \nCALGARY, Alberta - TheNewswire - January 10th, 2020, Voyageur Pharmaceuticals Ltd. (TSXV:VM) (the \"Company\" or \"Voyageur\") is pleased to announce the formulation and registration submission of Natural and Non Prescription Drug (NNHP) applications to Health Canada's for one additional radiographic product named MultiXthin. \n\n \n \nMultiXthin is a specially formulated, low density, pre-mixed barium suspension product. It will be sold in a 2-liter container and is for multiple testing applications. Barium sulfate suspension is for oral consumption to aid in radiographic x-ray procedures to view the upper gastrointestinal tract (esophagus, stomach, duodenum). MultiXthin is similar in composition to the dry powdered MultiXba. However, the barite has been pre-mixed in solution with 60% barium and is designed to provide ultra-fine particle distribution for superior coating of the GI Trac.\n\n \n \nVoyageur is continuing to develop multiple products and is currently developing its iopamidol-based Iodine contrast named IoX. The IoX product line is the focus in the near term for submission to Health Canada .\n\n \n \nAbout Voyageur\n\n \n \nVoyageur Pharmaceuticals Ltd. is a Canadian public company listed on the TSX Venture Exchange under the trading symbol VM. Voyageur is focused on the development of Active Pharmaceutical Ingredients (API) minerals. The current focus is developing barite and Iodine radiocontrast products and developing bromine-based pharmaceutical products.\n\n \n \nVoyageur's goal is to generate positive cash flow from operations through its signed joint venture with Chief Medical Supply Ltd. - Alberta's only pharmaceutical manufacturer. The joint venture contemplates turnkey manufacturing, bottling and distribution of barium radiopharmaceuticals for MRI, X-ray and CT scan applications. The Company also contemplates similar Health Canada registration applications for iodine and bromine products also for medical applications. Voyageur owns 100% interest in three barium sulfate (\"Barite\") deposits including two properties suitable in grade for the industrial barite market place, as well as a significant interests in a high-grade iodine, lithium & bromine brine project in Utah, US...